NovoCure Limited (NVCR) Analysts See $-0.14 EPS; CSS Industries Has 1.15 Sentiment

February 15, 2018 - By Winifred Garcia

CSS Industries, Inc., a consumer products company, designs, makes, procures, distributes, and sells seasonal, celebrations, and craft social expression products principally to mass market retailers in the United States and Canada. The company has market cap of $174.46 million. The Company’s craft and celebrations consumer products include craft ribbon and buttons, sewing patterns, infant products, journals, all occasion boxed greeting cards, gift card holders, gift bags, gift wrap, floral accessories, memory books, scrapbooks, stationery, stickers, and other gift and craft items. It currently has negative earnings. The companyÂ’s seasonal consumer products comprise Christmas products, such as packaging ribbon and bows, boxed greeting cards, gift tags, gift card holders, gift bags, gift wraps, tissue papers, and decorations; Valentine products consisting of classroom exchange Valentine cards and other related Valentine products; Easter product, including Easter egg dyes and related Easter seasonal products; and back-to-school products, such as teachersÂ’ aids and other learning oriented products.

Analysts expect NovoCure Limited (NASDAQ:NVCR) to report $-0.14 EPS on February, 22.They anticipate $0.12 EPS change or 46.15% from last quarter’s $-0.26 EPS. After having $-0.13 EPS previously, NovoCure Limited’s analysts see 7.69% EPS growth. The stock increased 2.43% or $0.5 during the last trading session, reaching $21.05. About 585,675 shares traded. NovoCure Limited (NASDAQ:NVCR) has declined 0.43% since February 15, 2017 and is downtrending. It has underperformed by 17.13% the S&P500.

The stock decreased 3.43% or $0.68 during the last trading session, reaching $19.13. About 61,481 shares traded or 23.73% up from the average. CSS Industries, Inc. (CSS) has declined 5.69% since February 15, 2017 and is downtrending. It has underperformed by 22.39% the S&P500.

Euclidean Technologies Management Llc holds 1.83% of its portfolio in CSS Industries, Inc. for 66,465 shares. Adirondack Research & Management Inc. owns 125,429 shares or 1.41% of their US portfolio. Moreover, Walthausen & Co. Llc has 0.78% invested in the company for 289,661 shares. The Pennsylvania-based Minerva Advisors Llc has invested 0.58% in the stock. Bridgeway Capital Management Inc, a Texas-based fund reported 156,108 shares.

NovoCure Limited engages in the development, manufacture, and commercialization of tumor treating fields for the treatment of solid tumors. The company has market cap of $1.88 billion. The firm markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. It currently has negative earnings. It is also involved in conducting clinical trials for the use of TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma.

Among 5 analysts covering NovoCure (NASDAQ:NVCR), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. NovoCure had 6 analyst reports since October 27, 2015 according to SRatingsIntel. Wedbush maintained NovoCure Limited (NASDAQ:NVCR) rating on Friday, July 29. Wedbush has “Outperform” rating and $20 target. The firm has “Outperform” rating given on Tuesday, October 27 by Wedbush. The rating was initiated by Deutsche Bank with “Hold” on Wednesday, December 2. JP Morgan initiated NovoCure Limited (NASDAQ:NVCR) rating on Tuesday, October 27. JP Morgan has “Overweight” rating and $29 target. Barclays Capital initiated NovoCure Limited (NASDAQ:NVCR) on Tuesday, January 19 with “Underweight” rating. The firm earned “Market Outperform” rating on Tuesday, October 27 by JMP Securities.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Winifred Garcia

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: